Ke Ma

Ke Ma

Auto-generated profile, based on publicly available information

Ke Ma

Beijing Anzhen Hospital, Capital Medical University, China (K.M., J.Y., H.G., P.L., Z.D., Jing Zhang, C.Z., P.Y., C.H., S.Z., G.L., J.D., Yang Li, Yulin Li)

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Circulation Research
Verified
Journal Article
Closed access
PDF file
KMKe Ma
Ke Ma
JYJie Yang
Jie Yang
YSYihui Shao
Yihui Shao
PLPing Li
Ping Li
HGHongchang Guo
Hongchang Guo
YLYulin Li
Yulin Li
Background: Accurate prediction of death is an unmet need in patients with acute decompensated heart failure (HF). Arachidonic acid (AA) metabolites play an important role in the multiple pathophysiological processes. We aimed to develop an AA score to accurately predict mortality in patients with acute decompensated HF and explore the causal relationship between the AA predictors and HF. Methods: The serum AA metabolites was measured in patients with acute decompensated HF (discovery cohort n=419; validation cohort n=386) by mass spectroscopy. We assessed the prognostic importance of AA metabolites for 1-year death using Cox regression and machine learning approaches. A machine learning-based AA score for predicting 1-year death was created and validated. We explored the mechanisms using transcriptome and functional experiments in a mouse model of early ischemic cardiomyopathy. Results: Among the 27 AA metabolites, elevated 14,15-DHET/14,15-EET ratio was the strongest predictor of 1-year death (hazard ratio, 2.10, P =3.1×10 −6 ). Machine learning-based AA score using a combination of the 14,15-DHET/14,15-EET ratio, 14,15-DHET, PGD2, and 9-HETE performed best (area under the curve [AUC]: 0.85). The machine learning-based AA score provided incremental information to predict mortality beyond BNP (B-type natriuretic peptide; ΔAUC: 0.19), clinical score (ΔAUC: 0.09), and preexisting Acute Decompensated Heart Failure National Registry, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure, and Get With The Guidelines Heart Failure scores (ΔAUC: 0.17, 0.17, 0.15, respectively). In the validation cohort, the AA score accurately predicted mortality (AUC:0.81). False-negative and false-positive findings, as classified by the BNP threshold, were correctly reclassified by the AA score (46.2% of false-negative and 84.5% of false-positive). In a murine model, the expression and enzymatic activity of sEH (soluble epoxide hydrolase) increased after myocardial infarction. Genetic deletion of sEH improved HF and the blockade of 14,15-EET abolished this cardioprotection. We mechanistically revealed the beneficial effect of 14,15-EET by impairing the activation of monocytes/macrophages. Conclusions: Our studies propose that the AA score predicts death in patients with acute decompensated HF and inhibiting sEH serves as a therapeutic target for treating HF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04108182.

15 December 2020 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
HGHongchang Guo
Hongchang Guo
KMKe Ma
Ke Ma
WHWenjing Hao
Wenjing Hao
YJYao Jiao
Yao Jiao
PLPing Li
Ping Li
YLYulin Li
Yulin Li
In response to pathological stimuli, the heart develops ventricular hypertrophy that progressively decompensates and leads to heart failure. miRNAs are increasingly recognized as pathogenic factors, clinically relevant biomarkers, and potential therapeutic targets. We identified that mir15a/mir16‐1 cluster was negatively correlated with hypertrophic severity in patients with hypertrophic cardiomyopathy. The mir15a/mir16‐1 expression was enriched in cardiomyocytes (CMs), decreased in hypertrophic human hearts, and decreased in mouse hearts after transverse aortic constriction (TAC). CM‐specific mir15a/mir16‐1 knockout promoted cardiac hypertrophy and dysfunction after TAC. CCAAT/enhancer binding protein (C/EBP)β was responsible for the downregulation of mir15a/mir16‐1 cluster transcription. Mechanistically, mir15a/mir16‐1 cluster attenuated the insulin/IGF1 signal transduction cascade by inhibiting multiple targets, including INSR, IGF‐1R, AKT3, and serum/glucocorticoid regulated kinase 1 (SGK1). Pro‐hypertrophic response induced by mir15a/mir16‐1 inhibition was abolished by knockdown of insulin receptor (INSR), insulin like growth factor 1 receptor (IGF1R), AKT3, or SGK1. In vivo systemic delivery of mir15a/mir16‐1 by nanoparticles inhibited the hypertrophic phenotype induced by TAC. Importantly, decreased serum mir15a/mir16‐1 levels predicted the occurrence of left ventricular hypertrophy in a cohort of patients with hypertension. Therefore, mir15a/mir16‐1 cluster is a promising therapeutic target and biomarker for cardiac hypertrophy.

17 June 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YLYang Li
Yang Li
KMKe Ma
Ke Ma
ZDZhujun Dong
Zhujun Dong
SGShijuan Gao
Shijuan Gao
JZJing Zhang
Jing Zhang
YLYulin Li
Yulin Li
Research advances over the past 30 years have confirmed a critical role for genetics in the etiology of dilated cardiomyopathies (DCMs). However, full knowledge of the genetic architecture of DCM remains incomplete. We identified candidate DCM causal gene, C10orf71, in a large family with 8 patients with DCM by whole-exome sequencing. Four loss-of-function variants of C10orf71 were subsequently identified in an additional group of492 patients with sporadic DCM from 2 independent cohorts. C10orf71 was found to be an intrinsically disordered protein specifically expressed in cardiomyocytes. C10orf71 -KO mice had abnormal heart morphogenesis during embryonic development and cardiac dysfunction as adults with altered expression and splicing of contractile cardiac genes. C10orf71 -null cardiomyocytes exhibited impaired contractile function with unaffected sarcomere structure. Cardiomyocytes and heart organoids derived from human induced pluripotent stem cells with C10orf71 frameshift variants also had contractile defects with normal electrophysiological activity. A rescue study using a cardiac myosin activator, omecamtiv mecarbil, restored contractile function in C10orf71 -KO mice. These data support C10orf71 as a causal gene for DCM by contributing to the contractile function of cardiomyocytes. Mutation-specific pathophysiology may suggest therapeutic targets and more individualized therapy.

4 February 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
JMJie Ma
Jie Ma
KMKe Ma
Ke Ma
JCJing Chen
Jing Chen
XYXinying Yang
Xinying Yang
FGFei Gao
Fei Gao
YLYulin Li
Yulin Li
Background: The early assessment of heart failure (HF) risk in patients with acute coronary syndrome (ACS) can help reduce mortality. S100A8/A9 is not only rapidly released after myocardial ischemia, but is also involved in reperfusion injury, which is an important predictor of HF after ACS. We attempted to construct a reliable HF risk stratification tool for evaluating patients with ACS after reperfusion therapy based on S100A8/A9 dynamic changes. Methods and Results: This prospective study included 3 independent cohorts of patients with ACS who received reperfusion therapy. The discovery cohort was divided into 2 subgroups: the longitudinal subgroup (n=264) with serum S100A8/A9 levels measured at admission and on days 1, 2, 3, and 4 postadmission, respectively, and the 2‐point subgroup (n=798) with S100A8/A9 levels measured at admission and on day 1 postadmission, respectively. Validation cohorts 1 (n=1399) and 2 (n=1183) both had S100A8/A9 levels measured on day 1 postadmission. HF events included in‐hospital HF events after the initial presentation and long‐term HF events after discharge. The median follow‐up for the discovery cohort, validation cohort 1, and validation cohort 2 was 4.2, 2.6, and 1.8 years, respectively. In the discovery cohort, S100A8/A9's predictive ability at day 1 surpassed other time points. Through the S100A8/A9‐guided risk stratification, patients deemed high risk (>7900 ng/mL) exhibited a higher 1‐year HF event rate (46% versus 2%, 38% versus 5%) than patients at low risk (<2100 ng/mL) in both validation cohorts. Among patients without left ventricular dysfunction after ACS, β‐blocker therapy correlated with reduced 1‐year HF events in intermediate‐to‐ high‐risk patients but not in low‐risk patients. Conclusions: S100A8/A9 levels on day 1 accurately classified patients at varying risks of HF, serving as a robust tool for HF risk prediction and treatment guidance. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03752515.

Verified
Journal Article
Open access
PDF file
HYHaixu Yu
Haixu Yu
WRWei Rong
Wei Rong
JYJie Yang
Jie Yang
JLJie Lu
Jie Lu
KMKe Ma
Ke Ma
JDJie Du
Jie Du
Background: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is associated with poor prognosis in cardiovascular diseases. However, the predictive value of TRAIL for the short-term outcome and risk stratification of acute pulmonary embolism (PE) remains unknown. Methods: This study prospectively included 151 normotensive patients with acute PE. The study outcome was a composite of 30-day adverse events, defined as PE-related death, shock, mechanical ventilation, cardiopulmonary resuscitation, and major bleeding. Results: Overall, nine of 151 (6.0%) patients experienced 30-day adverse composite events. Multivariable logistic regression showed that TRAIL was an independent predictor of study outcome (OR 0.19 per SD; 95% CI 0.04–0.90). An ROC curve revealed that TRAIL’s area under the curve (AUC) was 0.83 (95% CI 0.76–0.88). The optimal cut-off value for TRAIL was 18 pg/mL, with a sensitivity, specificity, negative predictive value, positive predictive value, positive likelihood ratio, and negative likelihood ratio of 89%, 69%, 99%, 15%, 2.87, and 0.16, respectively. Compared with the risk stratification algorithm outlined in the 2019 ESC guidelines, our biomarker-based risk stratification strategy (combining TRAIL and hs-cTnI) has a similar risk classification effect. Conclusion: Reduced plasma TRAIL levels predict short-term adverse events in normotensive patients with acute PE. The combination of the 2019 ESC algorithm and TRAIL aids risk stratification in normotensive patients with acute PE.

17 November 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
KYKexin Yao
Kexin Yao
JZJingyue Zhao
Jingyue Zhao
JYJie Yang
Jie Yang
JMJie Ma
Jie Ma
YLYulin Li
Yulin Li
KMKe Ma
Ke Ma
There is an urgent need for effective risk prediction tools to assess all-cause mortality in heart failure (HF) patients, and recent serum peptidomics advancements may help identify potential biomarkers associated with HF outcome. We aimed to provide insights into the multiple biological processes and assess the predictive values of serum peptidomics in HF. We performed a prospective, nested, case-control study of 108 patients with HF. The serum peptides were measured by mass spectrometry in 27 healthy controls (HC), 27 patients who experienced all-cause death (event group), and 27 patients matched for age and sex who survived (non-event group) during 1-year follow-up. Bioinformatics analysis was conducted to identify changes in signaling pathways during the development of HF and screen candidate circulating peptides. We identified 1343 and 215 differential expressed peptides in the comparison between HF and HCs group and between the event and non-event group, respectively. Biological pathway analysis showed that the differentially expressed peptides were both mainly enriched in the coagulation and complement and coagulation cascades pathway. In addition, we identified key peptides with potential predictive value for HF outcome, particularly the fibrinogen alpha chain (FIBA)-derived peptides. Our findings suggest that the complement and coagulation pathway was associated with HF outcome. A FIBA-derived serum peptides model can serve as an outcome classifier in patients with HF.